Skip to main content
OpenTrials
Completed

NCT Number: NCT02215109

Retinal Vessel Diameter in Branch Retinal Vein Occlusion

The authors investigated the consecutive change of retinal vessel's diameter in affected eye and fellow eye of Branch Retinal Vein Occlusion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Branch Retinal Vein Occlusion Cardiovascular Diseases Embolism and Thrombosis Eye Diseases Retinal Diseases Retinal Vein Occlusion Thrombosis Vascular Diseases Venous Thrombosis

Age range

40 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Dong Ho Park

Daegu, Kyungsangpookdo, 700-721, South Korea

About this study

Twenty five consecutive patients who had undergone intravitreal bevacizumab injection for Branch Retinal Vein Occlusion with macular edema were included in this study. All subjects were enrolled between April, 2012 and April, 2013 in the Department of Ophthalmology, Kyungpook National University Hospital.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Best-corrected visual acuity less than 20/40
  • Central subfield macular thickness (CSMT) 300 μm or greater on spectral-domain optical coherence tomography

Exclusion criteria

  • Patients with recurrent BRVO
  • History of previous treatments for BRVO including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation
  • Patients with diabetes or dyslipidemia
  • IOP ≥ 22mmHg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy
  • High myopia (<-6 Diopters), high hyperopia (>6 Diopters) or a history of refractive surgeries
  • Co-existing retinal disease other than BRVO
  • Corneal diseases include ulcer, keratoconus and a history of corneal laceration
  • Cataract and other media opacities resulting in visual impairment or poor fundus images

Treatment and study plan

Primary outcomes

  1. Unoccluded retinal vessel diameter of Branch Retinal Vein Occlusion

    Time frame: 0, 1, 3, and 6 months

    To evaluate the change of unoccluded retinal vessel diameter in affected eye of Branch Retinal Vein Occlusion and unaffected fellow eye.

Sponsors and collaborators

Lead sponsor

Kyungpook National University Hospital

Other

Registry information

Official study title

Change of Retinal Vessel Diameter in Branch Retinal Vein Occlusion After Intravitreal Bevacizumab Injection

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Aug 13, 2014
Registry last updated
Aug 30, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.